Clinical trials: Neoplasm, Brain
Malignant Brain Stem Tumor, Glioma
Anlotinib to Malignant Brainstem Glioma
This study is a single-arm, open-label, phase II study of anlotinib combined with radiation in the treatment of patients with malignant brainstem glioma.
- Trial name
- NCT04668508
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang Cancer Hospital
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Autoimmune encephalitis is an autoimmune disease of the central nervous system that targets neuronal autoantigens. Anti-neuronal autoantibodies are produced in patients, with anti-NMDAR antibody being the most common.Anti-NMDAR…
- Trial name
- RADIA (NCT06867991)
- Testing
- Ofatumumab combined with daratumumab, Ofatumumab, Repeated intravenous immunoglobulin/plasma exchange therapy
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- The First People's Hospital of Changzhou
Brain Tumor
Study of Letrozole in Recurrent Gliomas
The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.
- Trial name
- NCT03122197
- Testing
- Letrozole Oral Tablet, Temozolomide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Cincinnati
Spasticity Secondary to Either a Disorder or Trauma, Spinal Cord Injury (SCI)
Myobloc Atrophy Study
The present pilot study is designed to assess the extent to which BOTOX and MYOBLOC cause muscle atrophy in spastic patients. The primary objective is to assess whether there is statistically significant difference in muscle…
- Conditions
- Spasticity Secondary to Either a Disorder or Trauma, Spinal Cord Injury (SCI), Brain Injury, Tumor
- Trial name
- MAS (NCT02052024)
- Testing
- Botox, MYOBLOC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Georgetown University
Brain and Central Nervous System Tumors
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00486603
- Testing
- hydroxychloroquine, temozolomide, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma
Prognosis and Therapeutic Biomarkers for Glioblastoma Patients
The purpose of this study is to investigate if the potential biomarkers identified could be used for facilitating the diagnosis and prognosis of patients with glioblastoma (GBM).
- Trial name
- NCT03403803
- Testing
- Optune
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Brain and Central Nervous System Tumors, Melanoma (Skin)
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
RATIONALE: Radiation therapy such as boron neutron capture therapy may kill tumor cells without harming normal tissue. PURPOSE: Phase I/II trial to study the effectiveness of boron neutron capture therapy in treating patients who…
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00039572
- Testing
- boronophenylalanine-fructose complex
- Where
- 2 sites in United States
- Sponsor
- Beth Israel Deaconess Medical Center
Cancer, Neurological Disorder
Bolus Pouch Feed Study
The primary aim of this study is to evaluate the impact of introducing a new enteral tube feed on health and feeding related quality of life.
- Conditions
- Cancer, Neurological Disorder, Gastrointestinal Dysfunction, Oral Complication
- Trial name
- NCT05822557
- Testing
- Bolus Pouch Feed
- Where
- 15 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Nutricia UK Ltd
Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult
JDQ443 for KRAS G12C NSCLC Brain Metastases
The goal of this phase II clinical trial is to evaluate the intracranial efficacy of JDQ443, a KRAS G12C inhibitor in patients with KRAS G12C+ NSCLC and brain metastases (cohort A: asymptomatic, untreated brain metastases, cohort…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult, KRAS G12C
- Trial name
- STRIDER (NCT05999357)
- Testing
- JDQ443
- Sponsor
- Maastricht University Medical Center
Glioblastoma, Brain Tumors
Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma
This clinical trial aims to evaluate the feasibility and safety of early post-operative brain PET-MRI imaging in adult patients who have undergone surgery for suspected glioblastoma.
- Conditions
- Glioblastoma, Brain Tumors, Brain Imaging
- Trial name
- EARLYBRAINPET (NCT07274397)
- Testing
- Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Beta Emitting Accurate Monitored Systems
Brain Tumor - Metastatic
A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease
This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from…
- Trial name
- NCT04222062
- Testing
- Carmustine 7.7Mg Wafer
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Nebraska
Breast Cancer
Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
Basis: Brain metastasis is very common in breast cancer, and HER2 positivity is a risk factor for high incidence of brain metastasis, with approximately 50% of HER2+ MBC cases experiencing brain metastasis.
- Trial name
- NCT06015113
- Testing
- Disitamab Vedotin plus pyrotinib or naratinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xi'an International Medical Center Hospital
Lung Cancer
Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases
Patients will receive AZD9291 at a dose of 80 mg once daily. Intracranial response will be assessed with brain MRI scan, systemic evaluation will be done by PET-CT (Positron Emission Tomography-Computed Tomography) scan.
- Trial name
- NCT02736513
- Testing
- AZD9291
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Soroka University Medical Center
Glioblastoma Multiforme, Gliosarcoma
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I: The purpose of this research study is to determine the safety of the combination treatment of ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas, temozolomide (Temodar) and radiation…
- Trial name
- Zactima (NCT00441142)
- Testing
- ZD6474, temozolomide, Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 119 people
- Sponsor
- Patrick Y. Wen, MD
Mediastinal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Mediastinal Cancer, Metastatic Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00003941
- Testing
- bleomycin sulfate, filgrastim, cisplatin
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 222 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Glioblastoma, Newly Diagnosed Glioblastoma
REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
REMIND is a single-center feasibility study testing maintenance radiotherapy in adult patients with newly diagnosed glioblastoma.
- Conditions
- Glioblastoma, Newly Diagnosed Glioblastoma, Brain Tumor
- Trial name
- REMIND (NCT07831772)
- Testing
- Maintenance Radiotherapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Minnesota
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer
- Trial name
- NCT00003173
- Testing
- filgrastim, thiotepa, autologous bone marrow transplantation
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Dexmedetomidine, Postoperative Delirium
Dexmedetomidine Alleviates Postoperative Delirium After Brain Tumor Resections
Postoperative delirium (POD) is a common complication, and the incidence rate is about 25% in non cardiac surgery. Previous studies have reported that the total incidence of neurological pod ranged from 10% to 22%.
- Trial name
- NCT04674241
- Testing
- Dexmedetomidine, 0.9% saline
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Beijing Tiantan Hospital
Non-Small Cell Lung Cancer (NSCLC)
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02521051
- Testing
- Alectinib, Bevacizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.